US FDA is updating its guidelines on compliance to "Part 11" electronic signature and record rules for clinical trials to catch up to today's technology, but the agency emphasizes in new draft guidance that it will maintain its "narrow and practical interpretation" of the rules, including continued enforcement discretion in certain areas.
The agency issued a draft guidance June 20 to update from a 2003 guidance interpreting the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?